Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to show no change in quarterly revenue when it reports results on August 12 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Oramed Pharmaceuticals Inc is for a loss of 19 cents per share.
The mean earnings estimate of analysts was unchanged in the last three months.
This summary was machine generated August 8 at 21:41 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)